191. ウェルナー症候群 Werner syndrome Clinical trials / Disease details


臨床試験数 : 3 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031190141
19/03/202127/11/2019Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndromeProspective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome - EMPOWER Werner syndrome
Werner syndrome;C16.320.925 / C18.452.284.960
Subjects ingest oral capsules of NR (nicotinamide riboside) once daily (total daily dose: nicotinamide riboside 1000 mg).Yokote KoutaroNULLRecruiting>= 20age oldNot applicableBoth30Phase 1-2Japan
2NCT04512963
(ClinicalTrials.gov)
August 24, 20206/8/2020Phase I Study of Progerinin in Healthy VolunteersA Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy VolunteersHutchinson-Gilford Progeria Syndrome;Werner SyndromeDrug: Progerinin;Drug: PlaceboPRG Science & Technology Co., Ltd.Amarex Clinical ResearchCompleted18 Years45 YearsAll64Phase 1United States
3NCT00004815
(ClinicalTrials.gov)
May 199224/2/2000Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's SyndromeWerner's SyndromeDrug: growth hormoneNational Center for Research Resources (NCRR)National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);University of TexasCompletedN/AN/ABoth1N/ANULL